Epigenetics, an early event in the modulation of gene expression by inositol hexaphosphate in ethylnitrosourea exposed mouse lungs

Nutrition and Cancer

Volumn 63, Issue 1, 2011, Pages 89-99

  Pandey, Manuraj ^a   Gupta, Krishna P ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DNA METHYLTRANSFERASE 1; ETHYLNITROSOUREA; HISTONE DEACETYLASE 1; METHYL CPG BINDING PROTEIN 2; PHYTIC ACID; PROTEIN MLH1; PROTEIN P16; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MBD1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HYPERPLASIA; LUNG; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PROMOTER REGION; UPREGULATION;

ANIMALS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; ETHYLNITROSOUREA; FEMALE; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE 1; LUNG; METHYL-CPG-BINDING PROTEIN 2; MICE; PHYTIC ACID;

EID: 78751473671     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635581.2010.516868     Document Type: Article

References (58)

1. Meuwissen R and Berns A: Mouse models for human lung cancer. Genes Dev 19, 643-664, 2005.
2. Gupta KP, Singh J, and Bharathi R: Suppression of DMBA induced mouse skin tumor development by inositol hexaphosphate and its mode of action. Nutr Cancer 46, 66-72, 2003.
3. Raina K, Rajamanickam S, Singh RP, and Agarwal R: Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice. Clin Cancer Res 14, 3177-3184, 2008.
4. Vucenik I, Passaniti A, Vitolo MI, Tantivejkul K, Eggleton P, and Shamsuddin AKM: Anti-angiogenic activity of inositol hexaphosphate (IP6). Carcinogenesis 25, 2115-2123, 2004.
5. Mascaux C, Martin B, Paesmans M, Berghmans T, Dusart M, et al.: Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer 95, 139-145, 2006.
6. Xinrong Ma, Yang Q, Wilson KT, Kundu N, Meltzer SJ, and Fulton AM: Promoter methylation regulates cyclooxygenase expression in breast cancer. Breast Cancer Res 6, R316-R321, 2004.
7. Cooper WA, Kohonen-Corish MRJ, Chan C, Kwun SY, McCaughan B, et al.: Prognostic significance of DNA repairs proteins MLH1, MSH2, and MGMT expression in non-small-cell lung cancer and precursor lesions. Histopathology 52, 613-622, 2008.
8. Xinarianos G, Liloglou T, Prime W, Maloney P, Callaghan J, et al.: hMLH1and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. Cancer Res 60, 4216-4221, 2000.
9. Seng TJ, Currey N, Cooper W, Lee A, Chan C, et al.: DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 99, 375-382, 2008.
10. Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, et al.: p16 (INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 61, 3419-3424, 2001.
11. Esteller M, Corn PG, Baylin SB, and Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 61, 3225-3228, 2001.
12. Belinsky SA: Gene promoter hypermethylation as a biomarker in lung cancer. Nature Rev Cancer 4, 707-717, 2004.
13. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, and Herman JG: Aberrant patterns of DNA methylation, chromatin formation, and gene expression in cancer. Hum Mol Genet 10, 687-692, 2001.
14. Tsou JA, Hagen JA, Carpenter CL, and Laird-Offringa IA: DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 21, 5450-5461, 2002.
15. Laird PW: Early detection: the power and the promise of DNA methylation markers. Nat Rev Cancer 3, 253-266, 2003.
16. Chuang LSH, Ian HI, Koh TW, Ng HH, Xu G, and Li BFL. Human DNA-(Cytosine-5) methyltransferase-PCNA complex as a target for p21WAF. Science 277, 1996-2000, 1997.
17. Kimura H and Shiota K: Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J Biol Chem 278, 4806-4812, 2003.
18. Lin X and Nelson WG. Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. Cancer Res 63, 498-504, 2003.
19. Patra SK, Patra A, Zhao H, Carroll P, and Dahiya R: Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. Biochem Biophys Res Commun 302, 759-766, 2003.
20. Muller HM, Fiegl H, Goebel G, Hubalek MM, Widschwendter A, et al.: MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. Br J Cancer 89, 1934-1939, 2003.
21. Masamune N, Yoshinao O, Takashi E, Shin-ichi A, Takashi Y, et al.: Expression profile of class I histone deacetylase in human cancer tissues. Oncology Reports 18, 769-774, 2007.
22. Hyeok J, Young P, Hong S, Jo P, Na C, et al.: The overexpression of histone deacetylase 1 and its relationship with p16 INK4a gene hypermethylation in pulmonary squamous cell carcinoma and adenocarcinoma. Korean J Pathol 43, 107-112, 2009.
23. Lopez-Serra L and Esteller M: Proteins that bind methylated DNA and human cancer: reading the wrong words. Br J Cancer 98, 1881-1885, 2008.
24. Das PM and Singal R: DNA methylation and cancer. J Clin Oncol 22, 4632-4642, 2004.
25. Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400-5413, 2002.
26. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415-428, 2002.
27. Vesselinovitch SD, Rao KV, Mihailovich NN, Rice JM, and Lombard LS: Development of broad spectrum of tumors by ethylnitrosourea in mice and the modifying role of age, sex, and strain1. Cancer Res 34, 2530-2538, 1974.
28. GoodrowT, Reynolds S, Maronpot R, andAnderson M: Activation ofK-ras by Codon 13 mutations in C57BL/6 x C3H F, mouse tumors induced by exposure to 1, 3-butadiene. Cancer Res 50, 4818-4823, 1990.
29. Herman JG, Graff J, Myohanen RG, Nelkin BD, and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93, 9821-9826, 1996.
30. Frommer M, Mcdonald LE, Millar DS, Collis CM, Wattt TF, Griggt GW, Molloyt P, and Paul C:Agenomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89, 1827-1831, 1992.
31. Cui X,Wakai T, Shirai Y, Hatakeyama K, and Hirano S: Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. Toxicol Sci 91, 372-381, 2006.
32. Davis CD, Ethus OU, and Finley JW: Dietary selenium and arsenic affect DNA methylation in vitro in caco-2 cells and in vivo in rat liver and colon. J Nutr 130, 2903-2909, 2000.
33. Sithanandam G, Ramakrishna G, Diwan BA, and Anderson LM: Selective mutation of K-ras by N-ethylnitrosourea shifts from codon 12 to codon 61 during fetal mouse lung maturation. Oncogene 17, 493-502, 1998.
34. Tuveson DAand Jacks T:Modeling human lung cancer in mice: similarities and shortcomings. Oncogene 18, 5318-5324, 1999.
35. Kakarlapudi N,Vernooy JH, Quan L, Fijneman RJA, andDemant P. Control of lymphocyte infiltration of lung tumors in mice by host's genes: mapping of four Lynf (Lymphocyte infiltration) loci. Cancer Immunol Immunother 57, 217-225, 2008
36. Bauer AK, Dwyer-Nield LD, and Malkinson AM: High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. Carcinogenesis 21, 543-550, 2000.
37. Bauer AK, Dwyer-Nield LD, Keil K, Koski K, and Malkinson AM: Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: a role in tumor promotion. Exp Lung Res 27, 197-216, 2001.
38. Mantovani A, Allavena P, Sica A, and Balkwill F: Cancer-related inflammation. Nature 454, 436-444, 2008.
39. Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, and Issa JPJ: Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res 60, 4044-4048, 2000.
40. Grønbæk K, Hother C, and Jones PA: Epigenetic changes in cancer. APMIS 115, 1039-1059, 2007.
41. Niklinska W, Chyczewski L, Laudanski J, Chyczewska E, and Niklinski J: Detection of p16 abnormalities in early-stage non-small cell lung cancer. Folia Histochem Cytobiol 39(Suppl 2), 30-32, 2001.
42. Belinsky SA, Nikula KJ, PalmisanoWA, Michels R, Saccomanno G, et al.: Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95, 11891-11896, 1998.
43. Kinney SRM, Smiraglia DJ, James SR, Moser MT, Foster BA, and Karpf AR: Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res 6, 1365-1374, 2008.
44. Yan Z, Ke K, Kai W, and Xu Y: Primary study on dnmts and mecp2 expression in lungs of mice induced by formaldehyde. In Proceedings of the IEEE, ICBBE 1st International Conference, 2007, pp. 244-247.
45. Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT, andWang YC: Alteration of DNA methyltransferases contributes to 5 CpG methylation and poor prognosis in lung cancer. Lung Cancer 55, 205-213, 2007.
46. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, and Laird PW: CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res 59, 2302-2306, 1999.
47. Bader S, Walker M, McQueen HA, Sellar R, Oei E, et al.: MBD1, MBD2, and CGBP genes at chromosome 18q21 are infrequently mutated in human colon and lung cancers. Oncogene 22, 3506-3510, 2003.
48. Jones PL, Veenstra GJC,Wade PA, Vermaak D, Kass SU, et al.:Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19, 187-191, 1998.
49. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, et al.: MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 23, 58-61, 1999.
50. Kn H, Bassal S, Tikellis C, and El-Osta A: Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL). Cancer Biol Ther 3, 989-994, 2004.
51. Gupta KP and Mehrotra NK: Differential effects of butyric acid on mouse skin tumorigenesis. Biomed Environ Sci 10, 436-441, 1997.
52. Dashwood RH, Myzak MC, and Ho E: Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 27, 344-349, 2006.
53. Goelz SE, Hamilton SR, and Vogelstein B: Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun 130, 118-126, 1985.
54. Momparler RL and BovenziV:DNAmethylation and cancer. J Cell Physiol 183, 145-154, 2000.
55. Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, and Yang CS: Reversal of hypermethylation and reactivation of p16INK4a, RARâ, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 11, 7033-7041, 2005.
56. Singh J and Gupta KP: Inositol hexaphosphate induces apoptosis by coordinative modulation of p53, Bcl-2 and sequential activation of caspases in 7, 12 dimethylbenz [a]anthracene exposed mouse epidermis. J Environ Pathol Toxicol Oncol 27, 209-217, 2008.
57. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, et al.: Tea polyphenol (?)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 63, 7563-7570, 2003.
58. Fang M, Chen D, and Yang CS: Dietary polyphenols may affect DNA methylation. J Nutr 137, 223S-228S, 2007.